Entyvio vs Xifaxan
Side-by-side cost comparison based on Medicare Part D data
Entyvio
Vedolizumab
Manufactured by Takeda
Xifaxan
Rifaximin
Manufactured by Salix/Bausch
Xifaxan costs 92% less per claim than Entyvio ($498.00 vs $6,319.00). A generic version of Xifaxan is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Entyvio | Xifaxan |
|---|---|---|
| Avg Cost Per Claim | $6,319.00 | $498.00 |
| Total Medicare Spending | $1.6B | $1.2B |
| Total Beneficiaries | 32,000 | 298,000 |
| Total Claims | 248,000 | 2,480,000 |
| Annual Cost/Patient | $48,969.00 | $4,141.00 |
| Year-over-Year Change | +14.6% | +4.8% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Takeda | Salix/Bausch |
| Condition | GI/Acid Reflux | GI/Acid Reflux |
| Generic Name | Vedolizumab | Rifaximin |
Entyvio vs Xifaxan: What the Data Shows
Entyvio (Vedolizumab) and Xifaxan (Rifaximin) are both used to treat gi/acid reflux. Based on Medicare Part D data, Xifaxan costs $498.00 per claim, which is 92% less than Entyvio at $6,319.00 per claim.
Medicare spent $1.6B on Entyvio and $1.2B on Xifaxan. In terms of patient reach, Xifaxan serves more beneficiaries (298,000 vs 32,000).
Year-over-year spending changed +14.6% for Entyvio and +4.8% for Xifaxan. Entyvio saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Xifaxan is cheaper at $498.00 per claim, compared to $6,319.00 for Entyvio. That makes Xifaxan about 92% less expensive per claim based on Medicare Part D data.
Yes, both Entyvio and Xifaxan are used to treat gi/acid reflux. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Vedolizumab and generic Rifaximin can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $1.6B on Entyvio covering 32,000 beneficiaries, and $1.2B on Xifaxan covering 298,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.